Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2018-08-13 Interim / Quarterly Rep…
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2018
2018-08-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 13, 2018, reporting the issuance of a press release announcing second quarter 2018 financial results and a company update. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 3070 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'MENU VS MEAL' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such SEC current reports that announce information but do not contain full financial data or detailed reports themselves.
2018-08-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 27, 2018, which reports on the departure and appointment of directors or principal officers, option grants to executives, and changes in compensation arrangements. The key content is about management changes and compensation approvals, not a full financial report or earnings release. The document does not contain financial statements or detailed financial analysis but focuses on management and board-related information. Therefore, it fits the category of Board/Management Information (MANG). The document length is 5631 characters, which is sufficient to contain substantive information rather than a brief announcement. Hence, the classification is MANG with high confidence.
2018-07-03 English
4
Director's Dealing
2018-06-29 English
4
Director's Dealing
2018-06-29 English
4
Director's Dealing
2018-06-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.